| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CELL.2017.01.010 |
| P698 | PubMed publication ID | 28129544 |
| P50 | author | Antoni Ribas | Q32649604 |
| Siwen Hu-Lieskovan | Q115922425 | ||
| Beata Berent-Maoz | Q123292881 | ||
| P2093 | author name string | Jeffrey A Sosman | |
| Chunying Song | |||
| Douglas B Johnson | |||
| Lu Sun | |||
| Roger S Lo | |||
| Xiangju Kong | |||
| Willy Hugo | |||
| Bartosz Chmielowski | |||
| Mark C Kelley | |||
| Elizabeth Seja | |||
| Blanca Homet Moreno | |||
| Jia Pang | |||
| Jesse M Zaretsky | |||
| Shirley Lomeli | |||
| Grace Cherry | |||
| P433 | issue | 3 | |
| P921 | main subject | metastatic melanoma | Q18975855 |
| P304 | page(s) | 542 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma | |
| P478 | volume | 168 |
| Q101166208 | A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival |
| Q91525186 | Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis |
| Q54960920 | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. |
| Q61795830 | Applying an innovative biodegradable self-assembly nanomicelles to deliver α-mangostin for improving anti-melanoma activity |
| Q96128485 | Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients |
| Q58773998 | Capturing functional long non-coding RNAs through integrating large-scale causal relations from gene perturbation experiments |
| Q64091796 | Case report: reinitiating pembrolizumab treatment after small bowel perforation |
| Q100955017 | Classification of gastric cancers based on immunogenomic profiling |
| Q60932213 | Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer? |
| Q98222326 | EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma |
| Q90291969 | Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors |
| Q50058145 | Emerging biomarkers for cancer immunotherapy in melanoma. |
| Q91291958 | Functional Genomic Complexity Defines Intratumor Heterogeneity and Tumor Aggressiveness in Liver Cancer |
| Q99553999 | GTF2IRD1 overexpression promotes tumor progression and correlates with less CD8+ T cells infiltration in pancreatic cancer |
| Q61846321 | Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma |
| Q42380545 | Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. |
| Q59800659 | Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine |
| Q90218507 | Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers |
| Q52719039 | High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis. |
| Q93054534 | Identification of Distinct Immune Subtypes in Colorectal Cancer Based on the Stromal Compartment |
| Q92591182 | Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer |
| Q91794766 | ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy |
| Q60375472 | Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms |
| Q56889756 | Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy |
| Q47101155 | Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis |
| Q57171695 | Immunotherapy Resistance by Inflammation-Induced Dedifferentiation |
| Q38685600 | Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis |
| Q89965765 | Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment |
| Q49501422 | Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. |
| Q64118165 | Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma |
| Q89871427 | Mechanisms of Resistance to PD-1 Checkpoint Blockade |
| Q34557699 | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. |
| Q96952383 | Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasis |
| Q90283161 | Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives |
| Q92823087 | Papillary Thyroid Carcinoma Variants are Characterized by Co-dysregulation of Immune and Cancer Associated Genes |
| Q91891970 | Sex-associated molecular differences for cancer immunotherapy |
| Q89719900 | Silencing of STAT3 via Peptidomimetic LNP-Mediated Systemic Delivery of RNAi Downregulates PD-L1 and Inhibits Melanoma Growth |
| Q92778091 | Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis |
| Q52320729 | Strategy to targeting the immune resistance and novel therapy in colorectal cancer. |
| Q90410951 | The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma |
| Q90281646 | The prognostic value of tumor mutational burden and immune cell infiltration in esophageal cancer patients with or without radiotherapy |
| Q38611235 | Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers |
| Q89838032 | Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes |
| Q91817083 | Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma |
| Q55401761 | Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide. |
Search more.